Nifty
:
24435.95
Sensex
:
77966.35
-35.75 (-0.15%)
-187.90 (-0.24%)
Nifty
Sensex
:
:
24435.95
77966.35
-35.75 (-0.15%)
-187.90 (-0.24%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
76/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
1205.00
12-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1190
  •  1205
  •  1151
  •  1191.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4567528
  •  5439009791.9
  •  1205
  •  835.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,20,099.46
  • 26.61
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,30,452.36
  • 0.08%
  • 4.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.01%
  • 0.60%
  • 5.45%
  • FII
  • DII
  • Others
  • 6.88%
  • 11.08%
  • 0.98%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.22
  • 12.43
  • 11.57

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.21
  • 17.76
  • 6.29

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.00
  • 17.62
  • 9.96

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.01
  • 22.08
  • 22.51

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.60
  • 3.65
  • 4.22

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.05
  • 14.18
  • 14.51

Earnings Forecasts:

(Updated: 08-08-2026)
Description
2026
2027
2028
2029
Adj EPS
67
0
4.61
45.44
P/E Ratio
17.99
-
261.39
26.52
Revenue
25.9
22.12
20.6
26488.3
EBITDA
30566.4
34036.5
37224.5
7084.39
Net Income
7470.68
8481.88
8852.52
4610.69
ROA
4283.35
5013.35
5386.63
11.72
P/B Ratio
0.34
0.88
0.29
4.34
ROE
3.58
3.15
2.78
17.44
FCFF
14.49
14.73
13.79
-834.79
FCFF Yield
3497.19
4298.7
4809.79
-0.7
Net Debt
2.95
3.63
4.06
211.89
BVPS
3495.26
1367.54
4097.93
277.87

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
8,017.00
6,573.70
21.96%
7,587.00
6,527.90
16.22%
6,864.50
5,269.10
30.28%
6,123.20
5,237.00
16.92%
Expenses
6,087.60
4,485.20
35.73%
5,677.50
4,402.40
28.96%
5,048.10
3,881.50
30.06%
4,521.50
3,821.00
18.33%
EBITDA
1,929.40
2,088.50
-7.62%
1,909.50
2,125.50
-10.16%
1,816.40
1,387.60
30.90%
1,601.70
1,416.00
13.11%
EBIDTM
24.07%
31.77%
25.17%
32.56%
26.46%
26.33%
26.16%
27.04%
Other Income
106.10
154.90
-31.50%
779.10
80.60
866.63%
111.40
57.50
93.74%
523.10
113.60
360.48%
Interest
156.00
84.70
84.18%
123.00
76.60
60.57%
129.90
32.00
305.94%
101.30
25.10
303.59%
Depreciation
554.70
238.10
132.97%
508.40
237.90
113.70%
359.60
229.00
57.03%
301.90
233.60
29.24%
PBT
1,306.60
1,920.60
-31.97%
1,659.70
1,672.00
-0.74%
1,353.40
1,184.10
14.30%
1,687.40
1,270.90
32.77%
Tax
354.20
434.00
-18.39%
318.40
423.20
-24.76%
388.30
179.50
116.32%
454.00
373.10
21.68%
PAT
952.40
1,486.60
-35.93%
1,341.30
1,248.80
7.41%
965.10
1,004.60
-3.93%
1,233.40
897.80
37.38%
PATM
11.88%
22.61%
17.68%
19.13%
14.06%
19.07%
20.14%
17.14%
EPS
9.42
14.58
-35.39%
12.65
11.64
8.68%
10.36
10.17
1.87%
12.51
9.06
38.08%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
28,591.70
27,148.40
23,241.50
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,904.90
9,376.50
Net Sales Growth
21.11%
16.81%
18.90%
13.40%
14.08%
4.90%
1.06%
8.26%
10.59%
26.97%
 
Cost Of Goods Sold
7,742.90
6,244.00
5,345.40
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
Gross Profit
20,848.80
20,904.40
17,896.10
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,248.00
6,311.50
GP Margin
72.92%
77.00%
77.00%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.28%
67.31%
Total Expenditure
21,334.70
19,958.40
16,348.00
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,057.50
7,472.30
Power & Fuel Cost
-
398.90
358.20
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
% Of Sales
-
1.47%
1.54%
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.78%
1.86%
Employee Cost
-
3,978.40
3,289.70
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
% Of Sales
-
14.65%
14.15%
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.82%
15.84%
Manufacturing Exp.
-
3,968.80
3,464.70
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
% Of Sales
-
14.62%
14.91%
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.12%
10.19%
General & Admin Exp.
-
894.50
933.50
625.00
620.30
506.70
357.90
582.60
462.60
398.70
466.00
% Of Sales
-
3.29%
4.02%
3.20%
3.60%
3.35%
2.48%
4.09%
3.51%
3.35%
4.97%
Selling & Distn. Exp.
-
3,454.40
2,208.40
1,800.10
1,674.60
1,373.30
1,444.70
1,468.40
1,154.10
1,129.40
916.80
% Of Sales
-
12.72%
9.50%
9.21%
9.71%
9.09%
10.03%
10.30%
8.77%
9.49%
9.78%
Miscellaneous Exp.
-
1,019.40
748.10
649.80
595.20
548.90
548.90
525.90
371.20
336.00
916.80
% Of Sales
-
3.75%
3.22%
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
2.82%
4.37%
EBITDA
7,257.00
7,190.00
6,893.50
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,847.40
1,904.20
EBITDA Margin
25.38%
26.48%
29.66%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.92%
20.31%
Other Income
1,519.70
1,794.60
459.60
369.40
474.60
390.70
75.00
117.10
208.50
133.00
147.10
Interest
510.20
438.90
191.00
81.20
129.90
127.00
186.40
341.80
195.80
110.80
63.10
Depreciation
1,724.60
1,408.00
915.80
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
PBT
6,007.10
7,137.70
6,246.30
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,330.80
1,614.90
Tax
1,514.90
1,594.70
1,411.90
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
Tax Rate
25.22%
24.09%
23.43%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.21%
7.98%
PAT
4,492.20
4,942.90
4,467.70
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,731.80
1,456.60
PAT before Minority Interest
4,412.50
5,026.40
4,614.80
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,766.40
1,485.70
Minority Interest
-79.70
-83.50
-147.10
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
PAT Margin
15.71%
18.21%
19.22%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.55%
15.53%
PAT Growth
-3.14%
10.64%
20.16%
98.80%
-14.81%
1.91%
87.68%
-36.30%
4.05%
18.89%
 
EPS
45.03
49.55
44.79
37.27
18.75
22.01
21.60
11.51
18.06
17.36
14.60

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
27,111.40
23,953.10
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
Share Capital
100.60
100.60
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
27,010.80
23,852.50
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
Non-Current Liabilities
5,003.90
-542.10
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
Secured Loans
6.50
0.00
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
Unsecured Loans
3,181.50
0.00
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
Long Term Provisions
445.30
383.90
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
Current Liabilities
15,711.90
9,041.60
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,072.00
5,305.80
Trade Payables
2,845.10
2,280.70
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
Other Current Liabilities
7,620.40
2,524.30
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,473.90
1,212.10
Short Term Borrowings
4,401.60
3,169.50
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
Short Term Provisions
844.80
1,067.10
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
Total Liabilities
50,298.00
34,857.90
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,129.70
14,325.20
Net Block
24,105.80
13,133.70
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
Gross Block
34,309.80
21,699.80
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
Accumulated Depreciation
10,204.00
8,566.10
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
Non Current Assets
30,391.90
17,811.80
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
Capital Work in Progress
3,698.50
2,691.90
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
Non Current Investment
1,764.10
1,556.70
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
Long Term Loans & Adv.
776.60
400.10
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
Other Non Current Assets
46.90
29.40
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
Current Assets
19,906.10
17,046.10
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,200.50
6,022.30
Current Investments
5,775.80
4,855.50
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
Inventories
5,628.10
3,944.00
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
Sundry Debtors
5,415.70
4,084.80
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
Cash & Bank
1,416.60
2,956.80
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
Other Current Assets
1,669.90
500.60
664.20
274.00
1,575.40
1,265.30
1,085.50
1,080.50
1,019.20
348.50
Short Term Loans & Adv.
1,182.20
704.40
735.90
711.70
1,345.50
1,003.00
874.50
806.10
730.10
268.50
Net Current Assets
4,194.20
8,004.50
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,128.50
716.50
Total Assets
50,298.00
34,857.90
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,111.50
14,325.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
2,116.60
6,781.10
3,196.30
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
PBT
6,621.10
6,026.70
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
Adjustment
-289.80
1,020.40
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
Changes in Working Capital
-2,623.70
1,535.90
-902.70
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
Cash after chg. in Working capital
3,707.60
8,583.00
4,482.10
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,591.00
-1,801.90
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
Cash From Investing Activity
-8,296.10
-8,357.80
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
Net Fixed Assets
-826.80
-776.80
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
Net Investments
13.40
-4,208.50
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
Others
-7,482.70
-3,372.50
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
Cash from Financing Activity
5,806.90
1,995.30
-1,778.80
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
Net Cash Inflow / Outflow
-372.60
418.60
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
Opening Cash & Equivalents
826.80
413.00
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
Closing Cash & Equivalent
855.20
826.80
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
269.50
238.10
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
ROA
11.81%
14.77%
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
ROE
19.69%
21.08%
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
ROCE
21.39%
26.06%
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
Fixed Asset Turnover
1.85
2.20
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
Receivable days
33.55
37.17
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
Inventory Days
33.80
29.51
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
Payable days
149.82
150.48
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
Cash Conversion Cycle
-82.46
-83.79
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
Total Debt/Equity
0.43
0.13
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
Interest Cover
16.09
32.55
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Zydus Lifesciences’ arm enters into option and license agreement with Mereo
    12th Aug 2026, 09:29 AM

    The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States

    Read More
  • Zydus Lifesciences - Quarterly Results
    12th Aug 2026, 00:00 AM

    Read More
  • Zydus Lifesciences reports 36% decline in Q1 consolidated net profit
    11th Aug 2026, 18:16 PM

    Consolidated total income of the company increased by 20.72% to Rs 8,123.10 crore in Q1FY27

    Read More
  • Zydus Lifesciences launches REVAHALE
    10th Aug 2026, 17:48 PM

    REVAHALE addresses important challenges associated with inhaler-dependent therapies

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Indocyanine Green for Injection
    4th Aug 2026, 16:14 PM

    The product is indicated in adults and, for certain indications, in paediatric patients aged 1 month and older

    Read More
  • Zydus Lifesciences gets EIR from USFDA for injectable facility in Ahmedabad
    1st Aug 2026, 17:45 PM

    The GMP surveillance inspection was conducted from April 27 to May 05, 2026

    Read More
  • Zydus Lifesciences gets nod to conduct Phase III trial of Desidustat in sickle cell disease
    23rd Jul 2026, 10:47 AM

    The trial will enrol 164 patients diagnosed with the disease

    Read More
  • Zydus Lifesciences inks pact with Apollo Hospitals to expand access to Shield MCD test in India
    3rd Jul 2026, 14:22 PM

    The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types

    Read More
  • Zydus Lifesciences completes $166 million Assertio acquisition
    17th Jun 2026, 16:45 PM

    Assertio has become a wholly owned subsidiary of the company

    Read More
  • Zydus Lifesciences reports 9% rise in Q4 consolidated net profit
    19th May 2026, 16:00 PM

    Consolidated total income of the company increased by 16.84% at Rs 7,721.20 crore for Q4FY26

    Read More
  • Zydus Lifesciences’ arm inks definitive pact to acquire outstanding shares of Assertio
    14th May 2026, 10:11 AM

    The acquisition is expected to be completed in the financial year 2026-27 subject to customary conditions

    Read More
  • USFDA concludes GMP surveillance inspection at Zydus Lifesciences’ Ahmedabad facility
    6th May 2026, 13:06 PM

    The inspection closed with seven observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.